Kelsey K. Baker

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.”.

Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.732

N/A

0.104DataRank · unranked

1 citations

David B. Zhen, Marc R. Radke, Kelsey K. Baker, Andrew L. Coveler, Kit Man Wong +5 more

Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation Strategies

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.11.030

N/A

0DataRank · unranked

14 citations

Kelsey K. Baker, Paul A. Carpenter, Mary E.D. Flowers, Ted Gooley, Sarah E. Stevens +8 more

Use of medical aid in dying by individuals with cancer at a comprehensive cancer center.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e24073

N/A

0DataRank · unranked

1 citations

Courtney Daum, Kelsey K. Baker, Natalie F. Uy, Elisabeth McLean, Danielle Boekankamp +12 more

Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-22-1020

N/A

0DataRank · unranked

3 citations

Kelly Carter, Kelsey K. Baker, Mary W. Redman, Ting Wang, Kathy Vickers +15 more

Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.769

N/A

0DataRank · unranked

2 citations

Ali Raza Khaki, Mary W. Redman, Kelsey K. Baker, Aaron Lin, Brianna Woo +15 more